Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
LEGN heads into its November 12 earnings print with short interest building steadily, analyst targets being trimmed across the board, and retail attention spiking to an unusual high, all against a stock that has lost 9% over the past month to close at $18.62.
The short-side pressure has been accumulating quietly but persistently. Short interest now represents 8.6% of the free float, up 4.6% on the week and extending a build that has run since early September. That said, the borrow market itself shows no signs of stress. Cost to borrow has risen about 24% on the week to 0.63%, but that still puts it in low-single-digit territory, far from the levels that signal a hard-to-borrow situation. Availability is comfortable at 95%, meaning roughly one share is available in the lending pool for every share already borrowed. The 52-week low on availability was 24%, reached earlier in the year, so the current reading represents a notably relaxed borrow environment relative to what LEGN shorts have faced before. The ORTEX short score has eased from a recent peak of 74.7 in late September to 68.6 now, suggesting the acute short-side conviction of two weeks ago has softened somewhat without reversing. Options traders are not adding to the bearish tone: the put/call ratio of 0.42 is in line with its 20-day average and sits close to the 52-week low of 0.36, meaning call activity continues to dominate the options market with no meaningful tilt toward downside protection.
The Street paints a picture of acknowledged commercial progress but a valuation that still requires a lot to go right. JP Morgan trimmed its target to $33 from $35 this week, maintaining a Neutral rating. RBC Capital moved in the same direction, shaving its Outperform target to $56 from $58. Both moves come on the heels of a wave of post-Q2 target cuts in August, when Oppenheimer downgraded to Perform and slashed its target from $75 to $40. The mean analyst price target now sits at $46.19 against a stock price of $18.62, a gap that reflects deep disagreement between the bulls and the market. The bull case rests on Carvykti's durability data, Q2 global sales of $657 million, an improving profitability trajectory, and the $965 million cash position. Bears point to bispecific antibody competition, the execution complexity of the J&J partnership, and a pipeline where key assets carry approval probabilities in the 25-30% range. The EV/EBITDA multiple of 16.2 has drifted higher over the past 30 days as the stock has fallen, a sign that the market is not yet pricing in the earnings acceleration the bulls forecast.
On the ownership side, FMR LLC stands out as the dominant long, reporting 14.8% of shares as of September 30 and adding over 3.2 million shares in the most recent period. BlackRock and Westfield Capital also added modestly in the same quarter. The activist register carries no 13D filer, and FMR's position is a passive 13G. The insider log is less conviction-driven than it appears: the September 24 cluster of director share awards were granted, not purchased, so they carry minimal signalling weight. The one genuine open-market transaction was a sale of roughly 27,370 shares by director Corazon Sanders on September 29 at $9.46, modest in dollar terms at around $259,000. The CFO also sold a small parcel that same week. Net insider activity over 90 days is slightly negative at roughly -$309,000. None of this looks alarming, but there is no open-market buying to counter the short-side narrative.
One data point worth flagging comes from the ORTEX alt data layer, where retail attention, measured as the combined z-score of English Wikipedia views and ORTEX stock page visitors, registered a reading of 4.16 as of September 28, a notably elevated spike relative to LEGN's own 90-day history. This is an attention metric, not a revenue or demand indicator, but the surge in retail interest ahead of earnings is worth noting given the stock's sharp year-to-date decline and the wide gap between current price and analyst targets.
The next concrete test is the November 12 earnings release. After the August print, the stock fell 1.5% on the day and dropped 6.5% over the following five sessions. That prior reaction, and the continued analyst target-trimming since, frames what to watch: whether Carvykti's Q3 revenue trajectory is convincing enough to close some of the gap between where the stock trades and where even the more cautious analysts on the Street have their targets.
See the live data behind this article on ORTEX.
Open LEGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
